

Contact:

Loraine V. Upham

Lori@CureDM.com

(505-515-1947)

CureDM Participates in 2017 BIT's 5th Annual World Congress of Diabetes

Wilmington, DE – July 11, 2017 – CureDM announces plans to participate in the 2017 5th Annual World Conference of Diabetes on July 12-14. The conference is being held in Prague, Czech Republic in conjunction with the 6th World Congress of Endocrinology. CureDM will participate with an Oral Presentation among the 150 presenters. The conference attracts attendees from all over the world to exchange ideas and learn about cutting edge technologies.

CEO, Loraine Upham will Co-Chair and present in the Track on Diabetes Drugs, Drug Targets and Pharmacotherapy. Upham will also participate as a panelist in the Keynote Forum Workshop. Upham explains, "This conference is attended not only by the big pharma partners we all want to hear from, but also the smaller, off-the-beaten trail technologies that are yet to be adopted. We look forward to the opportunity to network and share our strategic plans with potential collaborators from all over the world." CureDM is actively engaged in fundraising, clinical development planning and partnering to bring forth a novel treatment approach to diabetes with their lead compound, HIP2B. HIP2B is a human derived peptide therapeutic that stimulates proteomic pathways that lead to islet neogenesis that can restore islet mass by creating new, healthy islets. Both type 1 and type 2 indications are being pursued.

About CureDM

CureDM is a biopharmaceutical company focused on the discovery and development of new therapeutics that prevent, ameliorate, or reverse diseases of metabolism. CureDM was co-founded by a molecular biologist and two endocrinologists who experienced the unmet medical need in diabetes patients on a daily basis, which provided the motivation for the discovery of HIP2B. For more information about CureDM, visit www.curedm.com.

XXXX

XXXXXX